Respiratory tract neoplasm

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…

This phase 3 trial tests whether adding an experimental drug called izalontamab brengitecan to the standard targeted therapy osimertinib works better than osimertinib alone or with chemotherapy for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior…

This phase 2 trial tests a combination of two drugs, olomorasib and pembrolizumab, as a first treatment for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and a PD-L1 score between 1% and 49%. The main goal is to see how long patients live without t…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This phase 2 trial tests whether adding two experimental drugs, imzokitug and pumitamig, to standard chemotherapy helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 160 participants will receive either the three-drug combination …

This study tests a new combination of three drugs (nivolumab, ipilimumab, and nogapendekin alfa inbakicept) for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this treatment helps keep the cancer from growing longer than standard two-drug ther…

This study tests whether recakimab, an injectable drug that lowers cholesterol, can safely reduce high cholesterol caused by the lung cancer medication lorlatinib. The trial enrolls about 29 adults with advanced ALK-positive non-small cell lung cancer who developed high cholester…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This pilot study tests whether an inhaled drug called cromolyn sodium, already used for asthma, is safe and feasible for people with locally advanced lung cancer. The drug works by calming mast cells, which may play a role in tumor growth and treatment resistance. About 5 to 10 p…

This study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The…

This early-stage trial tests a new cell therapy called GK01 for people with advanced lung cancer who have not responded to standard treatments. The therapy uses a patient's own immune cells (T cells) that are specially prepared to attack the cancer. The main goal is to check safe…

This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…

This phase II trial tests a special type of radiation called lattice radiation therapy (LRT) combined with standard chemoimmunotherapy for people with stage III lung cancer that did not shrink enough after initial treatment. The LRT delivers high-dose radiation to specific spots …

This phase 4 trial tests whether combining two oral drugs—ensartinib and anlotinib—can shrink tumors or slow disease in people with ALK-positive non-small cell lung cancer that has become resistant to lorlatinib. About 80 adults with advanced (stage IIIB-IV) cancer will receive t…

This Phase 3 trial tests whether adding the experimental drug SYS6010 to standard immunotherapy can better prevent lung cancer from returning after surgery. About 570 adults with stage II-IIIB non-small cell lung cancer who did not respond well to pre-surgery treatment will be ra…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This phase 2 trial tests a new drug called AK146D1, given together with other cancer drugs, in 348 people with advanced non-small cell lung cancer that cannot be surgically removed. The study aims to see if the combination is safe and can shrink tumors. Participants will receive …

This phase 2 trial tests the drug trastuzumab deruxtecan (T-DXd) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has high levels of the HER2 protein. Participants receive T-DXd by IV every three weeks. The study measures how long the cancer stays und…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…

This phase 3 trial tests a new daily pill, GFH375, against standard chemotherapy (docetaxel) in 300 people with advanced KRAS G12D lung cancer that has worsened after prior treatments. The drug is designed to block the specific cancer-driving mutation. Participants are randomly a…

This phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…

This phase II trial tests a new approach for advanced non-small cell lung cancer that hasn't responded to standard treatments. It combines photoimmunotherapy (ASP-1929), a light-activated drug that targets cancer cells, with cemiplimab, an immunotherapy that boosts the immune sys…

This phase 3 trial tests whether a personalized radiation plan, which expands the treatment area based on each patient's tumor margins, can control nasopharyngeal cancer as well as the standard approach. The study includes 568 adults with newly diagnosed, non-metastatic disease. …

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This Phase 2 trial is testing a drug called firmonertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study uses a blood test (ctDNA) to decide if treatment should be adjusted over time. About 154 participants will receiv…

This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-phase study tests an inhaled mRNA immunotherapy for adults with advanced lung cancer or solid tumors that have spread to the lungs. The treatment is given as a dry powder through an inhaler. The main goal is to check safety and find the best dose, with 60 participants …

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This study tests a new drug (BL-M14D1) combined with an approved immunotherapy (atezolizumab) in 36 adults with extensive-stage small cell lung cancer that has no standard treatment. The goal is to see if the combination can shrink tumors and control the disease. Participants mus…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-phase study tests an oral drug called SNH-118110 in 240 adults with advanced solid tumors that have a specific genetic change (RET). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried other treatm…

This study tests whether adding a new drug called BL-B01D1 to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that can be removed with surgery. About 90 participants will recei…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests a new drug combination (SYS6010 plus enlonstobart) against the usual immunotherapy with chemotherapy for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). About 500 adults aged 18-75 who have not had prior treatment for their…

This study tests a new drug called HS-20122 in combination with other cancer medicines for people with advanced non-small cell lung cancer. The trial includes three different drug combinations depending on the patient's tumor type. The main goals are to check safety, find the bes…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This Phase 2 trial tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. 152 participants will be randomly assigned to receive either the new induction…

This study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…

This Phase 2 trial tests whether adding the antihistamine diphenhydramine to the immunotherapy drug toripalimab and standard chemotherapy helps shrink tumors more effectively in people with operable non-small cell lung cancer. About 120 participants will receive either the combin…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how m…

This study tests whether adding a new drug (BL-B01D1) to the standard pill osimertinib can help people with a certain type of Stage III lung cancer stay cancer-free longer. Participants must have an EGFR gene mutation and have already completed chemotherapy and radiation without …

This study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…

This study tests whether giving a Pfizer-BioNTech COVID-19 mRNA vaccine before standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes for people with stage 4 non-small cell lung cancer. Researchers will enroll 500 adults to see if the vaccine helps the immun…

This phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination …

This phase 2 trial tests whether combining SX-682 (a drug that blocks certain immune-suppressing proteins) with atezolizumab (an immunotherapy) can shrink tumors in people with advanced non-small cell lung cancer that has worsened after chemotherapy and immunotherapy. About 32 ad…

This Phase 2 trial tests whether giving a combination of amivantamab and either lazertinib or chemotherapy before surgery can shrink or stop the growth of EGFR-mutated non-small cell lung cancer. About 68 people with stage II-IIIB lung cancer that can be surgically removed will p…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This trial tests whether an intelligent breathing exercise device helps people recover lung function after surgery for non-small cell lung cancer. Participants use the device for breathing exercises twice daily for 30 days after surgery, while a comparison group receives standard…

This study is testing two remote programs—a chatbot app called QuitBot and a text messaging service—to help American Indian and Alaska Native adults quit smoking. About 772 participants will be randomly assigned to one of the programs. The goal is to see which approach works bett…

This pilot study tests whether an inhaled drug called AER101 can reduce glycolysis—the process cancer cells use to break down sugar for energy—in early-stage non-small cell lung cancer. Participants inhale the drug three times daily for two weeks before their scheduled surgery. T…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether adding tarlatamab to durvalumab after standard chemotherapy and radiation can delay cancer return and extend life in people with limited-stage small cell lung cancer. Tarlatamab works by helping immune cells recognize and attack cancer cells. About 430 pa…

This phase III trial will enroll 854 Hispanic adults who smoke and want to quit. Participants will use the iCanQuit smartphone app, which teaches skills to manage cravings and prevent relapse. Half will also receive nicotine replacement therapy (gum, patch, or lozenge) to ease wi…

This phase 2 trial tests two different immunotherapy drug combinations (durvalumab with monalizumab or oleclumab) followed by personalized radiation for people with advanced non-small cell lung cancer that has a high PD-L1 score. The goal is to see which combination works better …

This phase 2 trial tests whether the drug becotatug vedotin can prevent cancer from returning in 140 patients with high-risk nasopharyngeal carcinoma who have completed standard chemo-radiation. Participants are randomly assigned to receive the drug or standard care. The main goa…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This Phase II trial tests a combination of two drugs, trastuzumab rezetecan and ivonescimab, in 30 people with advanced non-small cell lung cancer that has HER2 gene abnormalities. The goal is to see if the combo can control the cancer and delay progression. Participants must hav…

This study tests two treatment plans for people with lung cancer that has spread to the brain but is not causing major symptoms. One group gets focused radiation to all brain tumors first, then a new immunotherapy drug (ivonescimab) plus chemotherapy. The other group gets the imm…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This early-phase study tests two drugs together—navlimetostat and pumitamig—in people with advanced non-small cell lung cancer that has a specific genetic change (MTAP-deficient). The main goal is to find a safe dose and see if the combination helps shrink tumors. About 17 adults…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab), with or without radiation, as a first treatment for people with advanced non-small cell lung cancer that has a specific protein (EGFR) on its surface. About 39 participants will receive the drug…

This study compares two smartphone apps designed to help people stop smoking. One app uses a therapy that focuses on mood and behavior, while the other uses standard quitting advice. About 1,800 adult smokers who want to quit in the next month will use one of the apps for 30 days…

This phase 2 trial tests whether adding intermittent hypoxic training (IHT) – short sessions of breathing low-oxygen air – to standard chemo-immunotherapy can improve outcomes for people with stage II-IIIA lung squamous cell carcinoma. About 60 participants will receive either st…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…

This study tests whether taking only a few lymph node samples (selective sampling) works as well as removing all nearby lymph nodes (systematic dissection) in people with stage IIA-IIIB non-small cell lung cancer. All participants will first receive chemotherapy combined with imm…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to re…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and re…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with unresectable stage III non-small cell lung cancer. The study will enroll 84 participants and compare giving SHR-1701 before or after standard chemoradiation. T…

This study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-stage trial tests a new drug, AK138D1, alone or with another drug (ivonescimab) in people with advanced non-small cell lung cancer. The goal is to see if the treatment is safe and shrinks tumors. About 265 adults aged 18-75 with stage IIIB/IV cancer will take part.

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This study tests an experimental drug called DXC006 combined with either an immunotherapy drug (toripalimab) or standard chemotherapy (carboplatin or cisplatin) in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumor…

This early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also look…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This study tests whether adding a special type of radiation (SF-SBRT) to the usual combination of immunotherapy (toripalimab) and chemotherapy helps people with stage II-III non-small cell lung cancer live longer without the cancer coming back. About 200 participants will be rand…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This study tests a new drug combination (IBI3005) in about 282 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. Participants will be closely monitored for side effects a…

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This study tests a new drug called SCTB41 combined with the chemotherapy docetaxel in 90 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination is safe and works better than docetaxel alone. Participants will…

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…

This study tests a new drug called ALK202 combined with other medicines for people with advanced non-small cell lung cancer. The trial will include 252 participants and aims to see if the combinations are safe and can shrink tumors. It is divided into two phases: first to find th…

This Phase 3 trial tests a new drug called HRS-7058 against other KRAS G12C inhibitors in 450 adults with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has stopped responding to standard treatments. The study compares how well HRS-70…

This study tests whether giving sintilimab (an immunotherapy drug) together with chemotherapy can shrink advanced stage IIIC lung cancer enough to allow surgery. About 33 adults with previously untreated, unresectable non-small cell lung cancer will receive four cycles of the com…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and do…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests a new approach for lung cancer patients who are at high risk of incomplete tumor freezing during cryoablation. Before the freezing procedure, doctors will block small blood vessels near the tumor using a temporary, absorbable material. The goal is to make the fre…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This study tests an oral chemotherapy (paclitaxel) combined with immunotherapy given before surgery in patients aged 70-85 with non-small cell lung cancer. The goal is to see if this approach can shrink tumors enough to improve surgery outcomes and long-term survival. About 75 pa…

This early-stage study tests a new treatment called DCTY1102 for people with advanced cancers (like pancreatic, colorectal, or lung cancer) that have a specific genetic change (KRAS/NRAS G12D mutation) and a certain immune type (HLA-A*11:01). The treatment uses the patient's own …

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This Phase 3 trial tests whether adding an experimental drug called SYS6010 to the standard treatment osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer getting worse. About 680 participants will be random…

This Phase III trial will compare proton beam radiotherapy with standard photon radiotherapy in 504 patients with non-metastatic nasopharyngeal carcinoma. The goal is to see if proton therapy reduces toxic side effects and improves survival. Participants will be randomly assigned…

This study tests a new combination of two drugs, AMT116 and ivosimab, in people with advanced non-small cell lung cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18 to 75 will take part…

This study tests a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. It combines low-dose radiation to the chest with an immunotherapy drug (adebrelimab) and chemotherapy, followed by maintenance immunotherapy for up to t…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This phase 2 trial tests whether combining chidamide (a pill) with ivonescimab (an infusion) can help people with advanced non-small cell lung cancer whose tumors have stopped responding to immunotherapy and have a specific protein marker called YAP. The study will enroll 32 adul…

This study tests whether adding alpha lipoic acid (a strong antioxidant) to standard chemotherapy helps people with advanced non-small cell lung cancer. About 60 adults with stage III or IV lung cancer will take 600 mg of alpha lipoic acid daily alongside their chemo. Researchers…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial tests whether giving alectinib (a targeted pill) along with standard chemotherapy can shrink unresectable stage III ALK-positive lung cancer enough to allow surgery or radiation. About 50 people who have not had prior treatment will receive three cycles of the …

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…

This phase 2 trial is testing a drug called ivonescimab in 42 people with a type of head and neck cancer (nasopharyngeal carcinoma) that has stopped responding to standard immunotherapy and chemotherapy. The drug is given every 3 weeks by IV. Researchers will measure how many pat…

This study tests whether adding radiation to immunotherapy and chemotherapy can help people with advanced small-cell lung cancer that has spread to the liver. It includes 30 adults aged 18-75 whose cancer did not respond to or stopped responding to prior treatments. The goal is t…

This phase 2 trial tests whether fecal transplants from immunotherapy responders can improve outcomes in stage II-III non-small cell lung cancer. 68 patients will receive either standard treatment (Durvalumab + chemotherapy) or the same plus fecal transplant capsules. The main go…

This phase 2 study tests whether adding a PCSK-9 inhibitor (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 participants will receive either adebrelimab or retlirafusp alfa…

This study tests whether a special omega-3-enriched nutritional drink can improve nutrition in people with advanced lung or colorectal cancer who are at risk of malnutrition. About 118 participants will either get the drink plus dietary advice, or just dietary advice alone. The g…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This study tests whether adding a targeted chemoembolization procedure to standard immunotherapy can help people with stage IV lung squamous cell carcinoma live longer without their cancer growing. About 166 participants who have already responded to initial treatment will be ran…

This study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with a large, advanced type of lung cancer (stage III NSCLC) live longer without the cancer growing. About 204 adults aged 18-75 with tumors at least 5 cm wide or lymph nodes at least …

This phase 2 trial tests whether combining the immunotherapy drug tislelizumab with standard chemotherapy and a targeted chemo-blocking procedure (BACE) can shrink advanced, inoperable stage III non-small cell lung cancer enough to allow surgery. About 39 participants will receiv…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This Phase 2 trial tests whether combining two oral drugs, luvometinib and anlotinib, can shrink tumors in people with KRAS-mutated non-small cell lung cancer that has spread and stopped responding to prior treatment. About 48 adults will receive different dose combinations. The …

This study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This phase II trial tests a new treatment for non-small cell lung cancer using immune cells taken from the patient's own tumor. The cells are grown in a lab and then infused back to attack the cancer. The study will enroll 28 adults and measure how well the treatment shrinks tumo…

This study tests whether a drug called adebrelimab can help keep limited-stage small cell lung cancer from coming back after initial chemotherapy and radiation. About 200 adults aged 18-75 with untreated, limited-stage disease will be randomly assigned to receive either standard …

This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…

This study is for people with advanced non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. Many doctors avoid treating these patients due to risks of worsening ILD. The trial will test a specific chemotherapy as first t…

This phase 2 trial tests a new drug called vebreltinib combined with standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has MET overexpression and no other known genetic drivers. The study will enroll 19 participants to see if the …

This early study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced lung and colorectal cancers. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goal is to check for side effec…

This phase 3 trial compares three ways of giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed with surgery. Participants will receive toripalimab either before surgery (neoadjuvant), after surgery (adjuvant), or bo…

This study tests a new treatment for people whose nasopharyngeal cancer has come back and cannot be surgically removed. Participants will receive two cycles of a targeted drug (becotatug vedotin) plus an immunotherapy, followed by radiation and continued immunotherapy. The goal i…

This phase 2 trial tests whether adding an experimental immunotherapy (iparomlimab and tuvonralimab) to targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 people with stage I-IIB disease will receive the drug every 3 weeks for a year, star…

This Phase 2 trial tests a new drug called GFH375, alone or combined with other drugs (cetuximab or pemetrexed), as a first treatment for advanced non-small cell lung cancer with a specific KRAS G12D mutation. The study will enroll 90 people who have not had prior treatment. The …

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This phase 2 trial tests a drug called FHD-286 in 20 people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants take the drug by mouth once daily in 21-day cycles. The main goal is to see if the drug can shrink tumors.

This phase 2 trial tests whether adding the experimental drug rilapentib alpha to standard chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer that does not have certain gene mutations. Participants will receive the drug combination before su…

This phase 2 trial tests a combination of the drug zorifertinib plus chemotherapy delivered directly into the fluid around the brain and spine. It is for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain and s…

This early-stage trial tests a new drug called BL0020 combined with the immunotherapy Toripalimab in 33 people whose extensive-stage small cell lung cancer has returned after initial treatment. The main goal is to check safety and find the right dose, while also seeing if the com…

This study tests a drug called tarlatamab in 35 adults with small cell lung cancer that has spread to the brain but is not causing symptoms. The goal is to see if the drug can shrink or control these brain tumors. Participants must have already had standard chemotherapy and be in…

This phase 2 trial tests whether combining SKB264 (a chemotherapy) with anlotinib (a targeted therapy) can shrink tumors and control disease in people with advanced non-small cell lung cancer that has spread to the liver and stopped responding to standard EGFR-targeted drugs. Abo…

This study tests whether adding a cancer vaccine (CIMAVAX-EGF) to standard targeted drugs (sotorasib or adagrasib) can help control advanced lung cancer with a KRAS G12C mutation. About 29 adults with stage III or IV non-small cell lung cancer will receive the combination. The go…

This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) and a targeted therapy (anlotinib) to standard chemotherapy and radiation can help prevent cancer from returning in people with high-risk, advanced nasopharyngeal carcinoma. About 442 adults aged 18-65 …

This early-phase study tests an experimental oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have a specific KRAS mutation (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors.…

This phase 2 trial tests a combination of nab-paclitaxel (a chemotherapy drug) and local radiation therapy for people with extensive-stage small-cell lung cancer whose disease has worsened after initial treatment. The study aims to see if this combo can improve progression-free s…

This study tests a new combination of two drugs—gemcitabine (chemotherapy) and ivonescimab (a targeted therapy)—in people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if this combination can shrink tumors or sto…

This study tests a new combination of drugs (BL-B01D1 and tislelizumab) against standard chemotherapy plus tislelizumab as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. About 562 adults with good performance status will join th…

This phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemoth…

This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for people with a specific type of advanced lung cancer (stage III-N2b non-small cell lung cancer). The goal is to see if this treatment can completel…

This early-phase trial tests whether adding BLEX 404, a liquid extract from maitake mushrooms, to standard chemotherapy (pemetrexed + cisplatin) can help people with advanced non-small cell lung cancer that has no EGFR mutation. The study will enroll 32 adults aged 20–70 who have…

This study tests a new treatment for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment before. It combines an immunotherapy drug (benmelstobart), a targeted therapy (anlotinib), and chemotherapy, followed by chest radiation. The goal is to see…

This study tests whether giving two drugs (vibecortamab and putilimab) before surgery can help shrink tumors in people with locally advanced laryngeal cancer. About 10 adults aged 18-80 with resectable cancer will receive the combination, then have surgery. The main goal is to se…

This early-phase study tests a new drug called HLX3902 in about 48 people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. The drug is designed to help the …

This study tests a new treatment for people whose nose and throat cancer has returned and cannot be removed with surgery. The treatment combines an immunotherapy drug (PD-1 antibody) with two chemotherapy drugs, followed by targeted radiation. The goal is to see if this approach …

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …

This study tests a device that uses both cold and radiofrequency to treat lung tumors during a standard bronchoscopy. Twenty people with early-stage lung cancer will receive the treatment before surgical removal of the tumor. The goal is to see if the device can safely and effect…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or stan…

This early study tests a robotic bronchoscopy system that aims to detect, sample, and treat small lung tumors in a single procedure. About 30 adults with suspicious lung nodules up to 3 cm who cannot or choose not to have surgery will participate. The system uses advanced imaging…

This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose cancer has already been treated. The goal is to see if the combination can shrink tumors. About 33 adults aged 18 to 75 with good perfor…

This early-phase study tests whether giving a small, focused dose of radiation to the center of a lung tumor can safely 'prime' the immune system before standard chemoradiation and immunotherapy. About 24 adults with stage III non-small cell lung cancer that cannot be removed by …

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or radiation can help control early-stage non-small cell lung cancer in people who cannot or choose not to have surgery. About 45 participants with specific EGFR gene mutations …

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This Phase II trial tests a combination of two drugs, JS212 and JS111, in about 35 people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to prior treatment. The study will first find the safest dose, then check how well the c…

This study looks at how safe and effective the drug SHR-A1811 is for Chinese patients with advanced or spreading non-small cell lung cancer that has a specific genetic change called HER2 alteration. About 1,000 adults will be followed as they receive the drug as part of their nor…

This Phase 2 trial tests two drug combinations for people with a specific genetic mutation (EGFR) in advanced non-small cell lung cancer. One group receives amivantamab plus lazertinib as first treatment; the other gets amivantamab plus chemotherapy after previous treatment stopp…

This study tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, in 50 people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if the treatment can shrink tumors enough to allow surgery, and to measure how long t…

This phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study ai…

This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Parti…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This study tests a new treatment called Y-90 FAPI for people with advanced non-small cell lung cancer that has stopped responding to standard therapies. The treatment delivers radiation directly to cancer cells by targeting a protein found on tumor-supporting cells. The goal is t…

This trial tests whether adding natural killer (NK) cells from healthy donors to standard chemoradiotherapy can reduce the risk of cancer returning in people with advanced nasopharyngeal cancer. The study has two phases: first, finding the safest dose of NK cells, then testing th…

This early-stage trial will test whether infusing a patient's own tumor-fighting immune cells (called TILs) is safe for people with early-stage non-small cell lung cancer that has multiple spots in the lungs. Researchers will collect immune cells from the tumor or lung fluid, gro…

This early-phase trial tests whether combining a patient's own immune cells (called TILs) with a targeted therapy drug can safely treat advanced lung cancer that has stopped responding to standard targeted treatment. Researchers will enroll 50 adults with EGFR-mutant non-small ce…

This early-stage trial tests injecting the chemotherapy drug cisplatin directly into lung tumors using a thin tube with a camera. The goal is to see if this approach is safe and can kill more cancer cells while causing fewer side effects than standard IV chemo. The study will enr…

This phase II trial tests whether combining two drugs—sacituzumab tirumotecan and toripalimab—given before surgery can shrink tumors in people with stage II to IIIB non-small cell lung cancer (NSCLC). About 38 participants will receive the drugs intravenously over several weeks, …

This study tests whether adding magnesium to standard chemo-immunotherapy helps people with advanced non-small cell lung cancer. About 230 participants will receive either magnesium or a placebo, as both tablets and infusions. Neither patients nor doctors know who gets what. The …

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This study tests a new drug combination (JSKN016, toripalimab, and carboplatin) given before surgery to people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the treatment can completely or mostly eliminate the tumor before the operatio…

This study tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer whose disease has worsened after initial treatment. About 53 adults with EGFR-mutant NSCLC and additional PIK3CA/AKT1/PTEN gene changes will receive the two dr…

This study tests two drugs together for people with advanced non-small cell lung cancer that has HER2 abnormalities. The drugs are SHR-A1811, which targets HER2, and ivonescimab, which boosts the immune system. The goal is to see if the combination can control the cancer longer. …

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This study tests whether combining two drugs, tislelizumab and nintedanib, can help control limited-stage small cell lung cancer after standard chemoradiation. About 20 adults with good performance status will receive this consolidation therapy. The goal is to delay cancer progre…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study is for people with a specific type of lung cancer (EGFR-positive adenocarcinoma) that has spread to the lining of the chest, causing fluid buildup. Researchers are testing whether combining a daily targeted pill (furmonertinib) with focused chest radiation can safely c…

This study tests a combination of three drugs (chidamide, toripalimab, and anlotinib) in 52 adults with recurrent or metastatic nasopharyngeal carcinoma that has failed at least one prior treatment. The goal is to find the safest dose and see how many patients' tumors shrink. Par…

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This study tests a combination of the targeted drug limertinib plus chemotherapy (etoposide and carboplatin) in 30 people with a specific type of lung cancer. These patients have a mutation in the EGFR gene and their cancer has changed from non-small cell to small cell lung cance…

This phase 2 trial tests a sequence of targeted therapy (garsorasib), immunotherapy (ivonescimab), and chemotherapy before and after surgery for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed. The goal is to see if this approach increases the …

This early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not …

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This study tests whether giving a dye called Cytalux a few days before surgery works as well as giving it closer to the operation. The dye makes tumors glow under a special light, helping surgeons remove them more completely. About 106 adults with suspected lung cancer or confirm…

This Phase 2 trial tests a combination of two drugs, tunlametinib and cetuximab β, in 55 people with advanced non-small cell lung cancer that has a KRAS mutation and has not responded to prior treatments. The goal is to see if the combo can shrink tumors and control the disease. …

This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…

This phase 3 study tests whether a new combination of drugs (HS-20093 plus adebrelimab) works better than the standard chemotherapy docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The trial plans to enroll 45…

This phase 2 trial tests a new drug called ILKN421H combined with the immunotherapy pembrolizumab in 80 people with advanced non-small cell lung cancer. The study includes patients who have already tried other treatments or are newly diagnosed with a specific biomarker. Researche…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This study compares two types of targeted therapy (first-generation vs third-generation EGFR TKIs) for people with advanced lung cancer that has a specific rare mutation called EGFR exon 19 deletion-insertion. About 94 participants will be randomly assigned to one of the two trea…

This early-stage trial tests a new gene-editing drug called EDB-102 in 15 people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to target and disable a specific cancer-caus…

This study looks at people with advanced non-small cell lung cancer that has spread to many places (more than five spots). It tests whether adding high-precision radiation to the main lung tumor, on top of standard drug therapy, helps them live longer and keeps the tumor from gro…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This phase II trial tests the drug cemiplimab, an immunotherapy, given before and after surgery for people with early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. About 33 participants will receive cemiplimab for three cycles, then undergo surg…

This Phase 3 trial compares an experimental drug called SYS6010 with the standard chemotherapy docetaxel in about 506 people with advanced non-squamous non-small cell lung cancer that has not responded to prior treatments. The study aims to see if SYS6010 can slow cancer growth o…

This study tests a combination of two drugs—CVL237 tablets and serplulimab injection—in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The trial aims to find the safest dose and see if the combo can shrink tumors or delay their growt…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This study compares two treatments for high-risk patients with early-stage non-small cell lung cancer: minimally invasive surgery (wedge resection) and stereotactic body radiation therapy (SBRT). The goal is to see which approach leads to longer disease-free survival and better q…

This study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help restore the immune system's ability to fight advanced non-small cell lung cancer in 15 patients whose disease worsened after prior immunotherapy. Participants …

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This early-phase trial is testing a combination of two drugs—izalontamab brengitecan (given by IV) and adagrasib (a pill)—in 18 adults with advanced KRAS G12C-mutant non-small cell lung cancer that has stopped responding to other treatments. The main goal is to check safety and s…

This phase 2 trial is testing whether a combination of the experimental drug QL1706, standard chemotherapy, and bevacizumab can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has specific gene changes and has stopped responding to targeted ther…

This phase 2 trial tests a new approach for advanced non-small cell lung cancer. It combines chemotherapy and immunotherapy with a special 'high-low mixed-dose' radiotherapy that gives a strong dose to large tumors and a lower dose to smaller ones. The goal is to shrink tumors fa…

This early-stage trial tests a new drug called BL0020 in 48 adults whose lung cancer has changed from one type (non-small cell) to another (small cell) after standard treatment. The drug is given by IV every three weeks. The goal is to see if it can shrink tumors and control the …

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 108 people who have not had prior treatment will receive the combination. The study is not yet recr…

This study tests a new targeted cancer pill called limertinib combined with brain radiation as a first treatment for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. The goal is to see if the combination can better control the brain tum…

This study looks at whether taking leucogen (a drug that raises white blood cell counts) from the start can prevent low white blood cells in people with RET fusion-positive non-small cell lung cancer who are taking pralsetinib. About 25 people who have not had prior treatment wil…

This early-stage trial is testing a new oral drug called HS-10504 combined with several other drugs given by IV in people with advanced non-small cell lung cancer that has worsened after previous treatment. The study will enroll about 400 participants and aims to find safe doses …

This study tests a new drug called befotertinib combined with radiation therapy for people with advanced non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The goal is to see if this combination can delay cancer growth. About 84 participants …

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This study tests whether adding an experimental immunotherapy (fianlimab) to standard treatment (cemiplimab plus chemotherapy) can better control pleural mesothelioma, a rare and aggressive cancer of the lung lining. About 126 people who have not yet been treated will receive one…

This Phase 2 trial tests a drug called ivonescimab, either alone or with chemotherapy, in people with advanced non-small cell lung cancer that has certain genetic changes. The study aims to see if the treatment can shrink tumors and control the cancer. About 46 participants will …

This study tests a drug called IBI363 given before surgery for people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the drug helps shrink or eliminate the tumor before the operation. About 10 participants will receive IBI363, and resea…

This Phase 2 trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and Pucotenlimab (an immunotherapy)—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study will enroll 30 adults and measure how long the cancer stay…

This study is testing a device called the HybridTherm® system, which uses freezing and radiofrequency heat to destroy small lung tumors during a routine bronchoscopy. The procedure is done before the patient's planned surgery to remove the tumor. The main goals are to see if the …

This phase 2 trial tests whether giving a combination of the immunotherapy drug camrelizumab and two chemotherapy drugs (paclitaxel and carboplatin) before surgery can improve outcomes for people with advanced oral cavity or larynx cancer. Fifty participants will receive three cy…

This study tests whether a blood test can identify people with advanced lung cancer who can be treated with immunotherapy alone instead of chemotherapy plus immunotherapy. The trial enrolls 275 adults with high PD-L1 levels and a low inflammation blood score. The goal is to see i…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study tests a combination of two drugs (adebrelimab and oral etoposide) in elderly or frail patients with small cell lung cancer. The goal is to see if this treatment can slow down the cancer's growth and improve outcomes. About 47 participants will receive the treatment, an…

This trial investigates whether a femtosecond laser combined with an artificial intelligence model can diagnose lung cancer from fresh tissue samples as accurately as the standard frozen section method. About 294 adults scheduled for lung surgery will have their tumor specimens e…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This study tests an artificial intelligence (AI) prototype designed to quickly evaluate tissue samples taken during a bronchoscopy, a procedure used to diagnose lung cancer. The AI analyzes microscope images of the samples to determine if they are adequate for diagnosis and wheth…

This early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets wo…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study is testing whether a blood test that looks for genetic changes (ctDNA) can help detect lung cancer early in people who have suspicious lung nodules found on CT scans. Researchers will collect blood samples from 200 participants in Hong Kong and Vietnam at the start and…

This study looks at whether certain blood inflammation markers can help doctors tell the difference between harmless, precancerous, and cancerous vocal cord growths. Researchers will check medical records of 250 adults who have been diagnosed with a vocal cord lesion. The goal is…

This study will enroll 2,250 adults with a family history of lung cancer to see if an AI model called Sybil can accurately predict future lung cancer from chest CT scans. Participants will provide previously taken CT images, and the AI will analyze them to estimate risk. The goal…

This study will test artificial intelligence algorithms that analyze video from routine endoscopies of the head and neck. The AI will try to detect, classify (benign vs. malignant), and outline lesions, comparing its performance to doctors and lab results. About 283 adults with s…

This study aims to see if a new blood test can accurately detect lung cancer by analyzing RNA from platelets. Researchers will collect blood samples from 240 adults with lung cancer or suspicious lung nodules. The goal is to validate whether this AI-powered test can distinguish b…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study will check if low-dose CT scans can find lung cancer early in 1,716 high-risk smokers in India. Participants get a baseline scan, and if anything looks suspicious, they are referred to a team of specialists for follow-up. The goal is to see if this screening method wor…

This study will test a new, disposable freezing catheter (Celsio) in 30 people who need a lung procedure. The catheter uses extreme cold to help diagnose or treat conditions like lung cancer and interstitial lung disease. Unlike current devices, it does not need a bulky console o…

This study will enroll 2,000 people aged 50 or older in Mexico, Costa Rica, Colombia, and Argentina who are at high risk for lung cancer due to smoking, wood smoke exposure, family history, or COPD. Participants will get a chest X-ray analyzed by artificial intelligence and a low…

This study tests whether a special dye, given before a bronchoscopy, can make lung tumors glow so doctors can see them more clearly. About 20 adults with a suspicious lung nodule or lymph node will receive the dye and then have a bronchoscopy with a special camera. The goal is to…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study will test whether low-dose CT scans can help find lung cancer early in high-risk smokers aged 50-79 in Hong Kong. About 15,000 participants will be randomly assigned to receive three rounds of CT scans or usual care. The main goal is to see if screening reduces lung ca…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study tests whether home-based breathing exercises and stationary bike workouts can improve lung health in 200 current and former smokers aged 50 and older. Participants will use a handheld breathing device and a stationary bike for 12 weeks. The goal is to see if these exer…

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study tests a vaccine called SurVaxM in 80 current or former heavy smokers at high risk for lung cancer. The vaccine trains the immune system to recognize and attack cells that produce a protein called survivin, which is common in cancer cells. The goal is to see if the vacc…

This study aims to find the best ways to increase lung cancer screening among current and former smokers aged 50-80 in community health centers. About 19,000 participants will receive text messages and clinic support to complete eligibility checks and low-dose CT scans. The goal …

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether removing a thin layer of tissue (pseudomembrane) from the back of the nose using a scope can prevent radiation-induced tissue death in patients with recurrent nasopharyngeal cancer who have had repeat radiation. About 40 adults in China will undergo the p…

This study tests whether a modified herbal mouthwash can prevent painful mouth sores caused by radiation therapy in people with head and neck cancer. About 156 participants will use either the herbal mouthwash or a placebo during their radiation treatment. The goal is to see if t…

This trial compares standard radiation therapy with a new method that specifically avoids damaging small airways in the lungs. The goal is to see if this airway-sparing approach helps patients with stage III non-small cell lung cancer retain better breathing function after treatm…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This trial compares early versus delayed acupuncture to reduce dry mouth caused by chemoradiation in head and neck cancer patients. Participants receive acupuncture either during chemoradiation or after, and their dry mouth symptoms are tracked for a year. The goal is to find the…

This pilot study tests whether using bright light therapy for an hour each morning, delivered through an iPad app, is tolerable for people with advanced melanoma or non-small cell lung cancer who are about to start immunotherapy. The idea is that synchronizing the body's internal…

This early-stage trial tests whether the drug ponsegromab can help adults with advanced non-small cell lung cancer who are losing muscle mass (cachexia). About 80 participants will receive either ponsegromab or a placebo. The study measures changes in muscle size and physical fun…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests a program called LiveWell, which teaches emotional coping skills to people with metastatic lung cancer who are feeling anxious or depressed. About 80 participants will either take the program or receive usual care. The goal is to see if the program is practical, …

This study tests a smart breathing exercise device for people recovering from lung cancer surgery. About 200 adults will either use the device for 30 days after surgery or receive standard care. The goal is to see if the device improves lung function, reduces shortness of breath,…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests a home-based app for lung cancer patients on combination drug therapy. The app helps patients track symptoms, get personalized advice, and receive nurse support during treatment breaks. Researchers will see if it reduces symptom burden and improves quality of lif…

This study tests whether a smartphone reminder app can help lung cancer patients stay physically active during radiation therapy. About 32 adults with lung cancer will use the app or standard care, and their daily step counts will be compared. The goal is to see if simple digital…

This study tests whether a 12-week exercise program, delivered via Zoom, is practical and helpful for older adults (65+) with cancer who live in rural areas. Participants will do two supervised exercise sessions per week. The goal is to see if the program improves quality of life…

This study tests if giving a long-lasting numbing medicine in two different places around the ribs and chest wall can reduce pain and the need for strong painkillers after robotic lung surgery. About 300 adults having this surgery will be randomly assigned to receive the numbing …

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study tests a new program called ADAPT, which is a type of talk therapy for lung cancer patients and their spouses. The goal is to help both partners feel less afraid of the cancer coming back. About 72 couples will try the program during chemotherapy or radiation and answer…

This study compares two ways to lift the soft palate during throat surgery to see which causes fewer injuries. About 138 people aged 2 to 70 who need this type of surgery will be randomly assigned to either the standard double-strap method or a new full-wrap method. The goal is t…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This phase 2 trial tests whether taking taurine (a common amino acid) can prevent or reduce severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. 130 patients will take taurine pills or receive standard care starting 3 days before radiation until 1 …

This study tests a LINE chatbot that gives visual, interactive tips to help lung cancer patients handle side effects from their targeted therapy. About 178 adults with advanced lung cancer will either get usual care or also access the chatbot. The goal is to see if the chatbot bo…

This study looks at whether a special oxygen device (high-flow nasal cannula) can prevent dangerously low oxygen levels in children aged 1 to 6 years who are sedated for a lung exam called bronchoscopy. About 430 children will be randomly assigned to receive either the high-flow …

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study is testing a program called Care and Connect, where trained volunteers provide support and information to people with lung cancer. The goal is to see if this program helps reduce distress and makes it easier for patients to get the care they need. About 50 adults with …

This study tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help advanced cancer patients who are losing weight and appetite—a condition called cachexia. About 66 adults with stomach, colorectal, or lung cancer will receive the treatment. Th…

This study will test whether mindfulness-based breathing exercises can help lung cancer patients who are undergoing chemotherapy feel less breathless and improve their quality of life. Sixty patients will be split into two groups: one will practice these breathing exercises for e…

This study looks at whether watching cartoons or listening to breath-synchronized interactive stories can help children aged 6-9 feel less afraid and more comfortable while using a nebulizer for breathing medication. About 96 children with respiratory conditions will be randomly …

This study tests whether a supervised exercise program, started two weeks before chemotherapy and continued for 16 weeks during treatment, can help adults aged 35 to 65 with breast, lung, or colon cancer tolerate chemotherapy better. The goal is to see if participants can receive…

This study tests whether doing special breathing exercises for a few weeks before lung cancer surgery can reduce problems like pneumonia and help patients leave the hospital sooner. 70 people scheduled for lung cancer surgery will be randomly assigned to standard care or standard…

This study tests whether a liquid form of megestrol acetate (a drug that stimulates appetite) can help malnourished people with non-small cell lung cancer gain weight while they receive standard chemotherapy. About 116 participants will be randomly assigned to get either the drug…

This study tests a home-based program of exercise and breathing techniques for people with lung cancer who are scheduled for surgery. The program lasts 8 weeks before surgery and 4 weeks after, using a smartphone app to guide patients. Researchers want to see if it improves fitne…

This study tests whether a supervised exercise program, done alongside chemotherapy or immunotherapy, can improve fitness and recovery in patients with locally advanced non-small cell lung cancer. 74 participants will be randomly assigned to either exercise training or usual care…

This study tests a special breathing tube with a built-in camera for people undergoing repeat lung surgery. The tube helps doctors see exactly where it is placed, which may reduce problems like mispositioning. The trial will compare this video tube to the standard tube in 500 pat…

This study tests a special care plan to help Chinese patients with advanced EGFR-mutated lung cancer who are taking the drug amivantamab. The plan focuses on preventing common side effects like blood clots, skin rashes, and infusion reactions. About 122 adults will join to see if…

This study compares two types of anesthesia for early-stage lung cancer surgery: one that lets patients breathe on their own and one that uses a breathing tube. Researchers want to see which method leads to a shorter hospital stay and less pain medication use. The study will incl…

This study tests whether a combination of two anti-nausea drugs (rolapitant and palonosetron) can prevent vomiting and severe nausea in 238 lung cancer patients receiving both chemotherapy and radiation. The goal is to improve comfort during treatment. Participants will be follow…

This study tests whether adding acupuncture to standard breathing exercises helps people recover lung function after surgery to remove a lung nodule. Half of the 56 participants will get acupuncture plus usual care, while the other half gets usual care alone. Lung function, pain,…

This pilot study tests whether a personalized exercise program is practical for 20 adults with stage II or III non-small cell lung cancer who are about to start treatment. Participants will follow the Precise Exercise Regimen for Cancer Care (PERCC) program before and after their…

This study looks at whether a two-week program of walking and breathing exercises before surgery for non-small cell lung cancer can help reduce pain, speed up recovery, shorten hospital stays, and improve quality of life. About 62 adults scheduled for surgery will be split into t…

This study compares a 'tubeless' approach to standard care for people having minimally invasive surgery to remove small lung nodules. The tubeless group gets a laryngeal mask instead of a breathing tube and no chest drain after surgery. The goal is to see if they recover better w…

This study tests if applying cold (cryotherapy) to the wrist before a blood draw from the artery can reduce pain. It involves 258 adults with chronic respiratory diseases who need this test. The goal is to find a simple, drug-free way to make the procedure less painful.

This study compares a newer anesthesia method where patients breathe on their own during lung surgery to the standard method using a breathing tube and machine. About 1,600 people having minimally invasive lung nodule removal will be randomly assigned to one of the two methods. T…

This study tests whether a nerve block given through a small port under the skin can help control chest pain in people with advanced lung cancer. The block delivers numbing medicine near the chest wall nerves. Researchers will compare pain levels and side effects in 180 patients …

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…

This study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…

This study compares two ways to rebuild the nose after partial or total loss: surgery using skin flaps, or a custom-made prosthetic nose (epithesis). Researchers will ask people who had either treatment at least one year ago to fill out a questionnaire about how their nose looks …

This study explores whether artificial intelligence can help perform high-field whole-body MRI scans faster while keeping image quality high. Researchers will compare standard MRI sequences with AI-accelerated versions in 600 adults undergoing screening for prostate, lung, or vas…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study will compare how quickly and how much THC enters the blood when people vape THC liquids versus smoking cannabis. Forty healthy adults who already use both products will try each method in a random order. Researchers will measure THC levels, side effects, and puffing be…

This study will enroll 1,500 current or former smokers aged 50-80 to see if an artificial intelligence (AI) model can help doctors better detect lung nodules and predict cancer spread. Participants will undergo CT scans, and the AI's results will be compared to standard radiologi…

This study uses blood tests (liquid biopsies) to track how small cell lung cancer changes during chemotherapy and immunotherapy. Researchers will analyze DNA from blood samples taken before, during, and after treatment in 50 patients. The goal is to understand why some cancers be…

This study will screen 477 current or former smokers in Brazil for lung cancer using CT scans. It aims to see how often the scans give false alarms (false positives) in a region where lung infections are common. The goal is to improve screening accuracy and reduce unnecessary fol…

This study explores whether a hair follicle or cheek swab can accurately measure a person's internal body clock (circadian rhythm) in patients with advanced lung cancer receiving immunotherapy. Researchers will use a new tool called TimeTeller to analyze gene activity from these …

This study tests a new way to see where an immunotherapy drug goes in the lungs of people with stage III lung cancer. Twenty participants will receive a small dose of a fluorescent version of the drug durvalumab, then have a special camera bronchoscopy to spot the drug in tumors …

This study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…

This study will enroll over 3,200 adults in Delhi and surrounding areas to understand how air pollution, especially fine particles (PM2.5), combines with other factors like smoking and genetics to increase lung cancer risk. Researchers will also look for biomarkers and identify g…

This study will develop an artificial intelligence model that uses a patient's series of CT scans over time to predict whether a lung nodule will grow or become cancerous. Researchers will analyze scans from nearly 5,000 people to train the AI to recognize different growth patter…

This observational study looks at adults with non-small cell lung cancer that has spread to the brain. Researchers want to see if getting radiation and immunotherapy 30 days apart or closer together changes how long the brain tumors stay stable and how long patients live. Partici…

This study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks at two different methods doctors use to re-inflate a lung after it has been collapsed during surgery. About 350 people having lung surgery will take part. The goal is to see which method leads to fewer lung problems like pneumonia or collapsed air sacs in the wee…

This study looks at a specific type of lung cancer called lung adenocarcinoma and how it can spread through tiny air spaces in the lungs. Researchers will collect tumor and healthy tissue samples from 140 patients to find genetic markers that might predict this spread. The goal i…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study tests whether personalized patient navigation can help more American Indian and Alaska Native people in Washington state get screened for lung cancer. About 237 adults aged 50-77 who smoke or recently quit will be enrolled. The goal is to see if tailored support helps …

This study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…

This early-stage study will give 8 healthy Chinese men a single dose of the experimental lung cancer drug zorifertinib, which has been tagged with a tiny amount of radioactivity. By collecting blood, urine, and stool samples over two weeks, researchers will track exactly how the …

This early-phase trial will test a new PET imaging agent called 64Cu-DOTA-pembrolizumab in 6 people with stage IV non-small cell lung cancer who are already on the immunotherapy drug pembrolizumab. The goal is to see if the imaging agent can safely tell the difference between tum…

This study looks at medical records of 3,000 adults with lung cancer to see if the stage at diagnosis is shifting to earlier, more curable stages. Researchers will track how often cancer is found through screening programs, chest X-rays, or heart scans. No new treatments or tests…

This study tests whether a specially designed educational toolkit, called the Lung Toolkit, can improve knowledge about lung cancer and screening among American Indian and Alaskan Native adults aged 50 to 80 who smoke cigarettes. The toolkit includes a website with resources and …

This study aims to find better ways to help Veterans quit smoking when they come in for lung cancer screening. Since smoking causes most lung cancers, combining screening with stop-smoking support could save more lives. The project will test new processes at a few VA sites and me…

This study aims to see how nicotine changes eye movements in people who use e-cigarettes. Researchers will measure things like how fast eyes move and how well they follow objects, along with blood nicotine levels and self-reported feelings. The goal is to find a more objective wa…

This study watches how well the drug repotrectinib works and what side effects it causes in Korean patients with a specific type of lung cancer or solid tumors that have certain gene changes. About 10 patients will be followed for up to 12 months during their normal treatment. Th…

This study compares a new electromagnetic navigation system to standard CT scans for guiding surgeons to small lung nodules during surgery. About 400 adults with nodules up to 2 cm will be randomly assigned to one method. The goal is to see which approach helps surgeons find and …

This study will look back at medical records of 300 people with advanced non-small cell lung cancer (NSCLC) whose disease got worse after first-line immunotherapy. Researchers want to see which second-line treatments were used and how well they worked in real-world practice. The …

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study looks at whether people with peripheral vascular disease (narrowed leg arteries) might also be at high risk for lung cancer because of shared smoking history. Researchers will check if these patients qualify for lung cancer screening and refer them for a low-dose CT sc…

This observational study will follow about 2,000 patients in China who have early-stage lung cancer with a specific gene mutation (EGFR) and have received targeted therapy pills (EGFR-TKIs) after surgery. Researchers will track how long patients live and how long they stay cancer…

This study tests whether a special headset (extended reality) can help surgeons plan the removal of cancer-affected lymph nodes in the neck for people with lung cancer. Ten patients will have their PET and CT scans combined into a 3D model that the surgeon views just before surge…

This study looks at how adults with lung nodules that might be cancer make decisions about their care before a final diagnosis. Researchers will use questionnaires to measure patients' confidence, doubts, and satisfaction with their choices. The goal is to find out what factors h…

This study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…

This study interviews about 85 patients with early-stage non-small cell lung cancer and 15 doctors to find out what makes it hard or easy to keep taking the drug osimertinib after surgery. The goal is to identify barriers like side effects, cost, or communication issues, and faci…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This observational study will enroll 300 people with suspected lung lesions to see if 3D ultrasound can measure them as accurately as CT scans. Participants will undergo both ultrasound and CT imaging, and researchers will compare the results. If the 3D ultrasound works well, it …

This study looks at how different surgical tools used during lung cancer surgery might affect coughing after the operation. About 248 adults having right lung surgery will be randomly assigned to one of two tool types. The goal is to find out which tool causes less nerve damage a…

This study tests whether the Apple Vision Pro headset can help surgeons see blood vessels more clearly during lung surgery. Twenty adults scheduled for lung surgery will have a CT scan before the operation, and the surgeon will wear the headset to view 3D images during the proced…

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This study follows 120 people with laryngeal cancer to see how their quality of life, voice, swallowing, pain, and mood change before treatment and at 3, 6, and 12 months after. Researchers will use questionnaires to track these changes. The goal is to better understand recovery …

This early-stage study looks at how the drug anecatibin fumarate is processed in the body of people with and without liver problems. It will include 24 adults with lung cancer. The goal is to understand safety and drug levels, not to test if the drug works.

This study will expose 24 healthy adults to different levels of wildfire smoke in a safe, controlled room to see how it affects their lungs and brain. Researchers want to understand why some people may be more vulnerable to long-term lung diseases like asthma, COPD, and lung canc…

This study will collect tumor samples and medical data from 150 adults with non-small cell lung cancer (stages I to IV) at Bordeaux University Hospital. Researchers will analyze the molecular, metabolic, and immune features of the tumors to understand how the cancer progresses an…

This study will use artificial intelligence to create a risk prediction model for head and neck cancers, including cancers of the throat and voice box. Researchers will collect data from 3000 participants, including their medical history, lifestyle habits, and laryngoscopy images…

This pilot study will check if tumor DNA in spinal fluid can predict brain metastases in 40 patients with stage III or IV non-small cell lung cancer. Participants will undergo a lumbar puncture to collect cerebrospinal fluid, plus blood draws and an MRI six months later. The goal…

This study will test if a simple, low-intensity cycling exercise combined with a handheld monitor can predict serious complications in lung cancer patients before surgery or other treatments. Researchers will include 500 adults with suspected lung cancer. The goal is to make risk…

This trial tests a new communication workflow called CORRECT that helps radiologists and radiation oncologists work together more effectively when planning radiation therapy for lung and head-and-neck cancers. About 194 patients will be involved, and doctors will use a shared sys…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study will test a new single-port surgical robot, called SHURUI, for chest surgeries like removing lung tumors or mediastinal masses. About 40 adults aged 18-75 who need these surgeries will take part. The goal is to see if the robot is safe and works well, with hopes of les…

This study looks at sputum and blood samples from 50 adults with advanced non-small cell lung cancer who are starting immunotherapy. Researchers want to find immune cell changes that could predict which patients will respond well to treatment. The goal is to better understand the…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study looks at whether an extra cleaning step during a common lung cancer staging procedure (EBUS) can reduce contamination of tissue samples. Researchers will collect samples from 204 adults with suspected lung cancer. The goal is to see if better cleaning leads to more acc…

This study will interview 120 cancer patients in Texas to learn what makes it easier or harder to get timely cancer treatment. Researchers will talk with patients by phone or video to understand their experiences across different cancer types and insurance plans. The goal is to i…

This study will enroll 63 people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. Participants will take part in a 3-month rehabilitation program that includes physical activity. Researchers will measure quality of life, hand grip stre…

This study looks at how cancer and its treatments change the way people experience food, including taste, mouth health, and overall eating pleasure. Researchers will ask 180 adults with different cancers to fill out a detailed questionnaire about their eating habits and feelings.…

This study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults wi…

This study tests whether extended reality (XR) can help doctors more accurately locate small lung nodules during CT scans. About 30 adults scheduled for lung nodule surgery will participate. The goal is to see if XR guidance improves precision and reduces complications.

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …

This early study tests whether applying low-intensity electric fields (TTFields) to the chest before lung cancer surgery is safe and affects cancer-related genes. About 18 adults with stage I-IIIA non-small cell lung cancer will wear a non-invasive device for a short time before …

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study looks back at medical records of 350 people with advanced non-small cell or small cell lung cancer who took anlotinib after their previous treatment stopped working. The goal is to see how well anlotinib works and how safe it is when used in later lines of therapy. The…

This study looks at patients with a type of throat cancer (nasopharyngeal carcinoma) whose tumors did not shrink after two rounds of chemotherapy. It compares two different next steps: switching to a different chemotherapy combination before radiation, or going straight to radiat…